yingweiwo

Ticagrelor (AZD6140)

Alias: AZD 6140; AZD 6140; AR-C 126532XX; AR-C-126532XX; AZD-6140; AZD6140; AR-C126532XX; Ticagrelor; brand name: Brilinta; Brilique; Possia
Cat No.:V1303 Purity: ≥98%
Ticagrelor (formerly AZD-6140; AR-C 126532XX; AZD6140;AR-C126532XX; Trade name: Brilinta; Brilique; Possia) is the first reversibly binding, potent and orally bioactiveP2Y12 receptor antagonist used as an antiplatelet and anticoagulant.
Ticagrelor (AZD6140)
Ticagrelor (AZD6140) Chemical Structure CAS No.: 274693-27-5
Product category: P2 Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
25mg
50mg
100mg
250mg
500mg
1g
2g
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Ticagrelor (formerly AZD-6140; AR-C 126532XX; AZD6140; AR-C126532XX; Trade name: Brilinta; Brilique; Possia) is the first reversibly binding, potent and orally bioactive P2Y12 receptor antagonist used as an antiplatelet and anticoagulant. It inhibits P2Y12 receptor with a Ki of 2 NM. Ticagrelor was approved in 2011 by FDA as an antiplatelet drug for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. Like the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible.

Biological Activity I Assay Protocols (From Reference)
ln Vitro
Compared to other P2Y12R antagonists, ticagrelor encourages a higher suppression of adenosine 5′-diphosphate (ADP)-induced Ca2+ release in ischemic platelets. Beyond its antagonistic effects on P2Y12R, ticagrelor also inhibits the equilibrative nucleoside transporter 1 (ENT1) on platelets, which causes extracellular adenosine to accumulate and Gs-coupled adenosine A2A receptors to become activated[1]. When compared to mice treated with saline, B16-F10 cells show less interaction with platelets from mice treated with ticagrelor[2].
ln Vivo
Mice given a therapeutic dose of ticagrelor (10 mg/kg) in B16-F10 melanoma intravenous and intrasplenic metastatic models show significant decreases in lung (84%) and liver (86%) metastases. In addition, animals treated with ticagrelor have higher survival rates than those treated with saline. Similar results are seen in a 4T1 breast cancer model, where ticagrelor therapy reduces lung (55%) and bone marrow (87%) metastases[2]. Titicagrelor (1–10 mg/kg) administered orally once has a dose-related inhibitory impact on platelet aggregation. When ticagrelor is administered at its maximum dosage of 10 mg/kg, platelet aggregation is significantly inhibited beginning one hour after medication and reaches its peak four hours later[3].
Animal Protocol
Mice: Female BALB/c mice are inoculated subcutaneously in the fourth mammary pad with 4T1 breast cancer cells. Once a tumor is palpable, mice receive daily injections of PBS or ticagrelor (10 mg/kg). One week later, mice undergo primary tumor resection. At 28 days mice are sacrificed and lungs, femurs and tibiae harvested. Dissociated cells from lung and bone marrow are plated in medium containing 60 μM 6-thioguanine. After 14 days, culture plates are fixed with methanol and stained with 0.03% methylene blue to enumerate metastatic 4T1 colonies.
Mice bearing B16-F10 melanoma tumor
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Ticagrelor is 36% orally bioavailable. A single 200mg oral dose of ticagrelor reaches a Cmax of 923ng/mL, with a Tmax of 1.5 hours and an AUC of 6675ng\*h/mL. The active metabolite of ticagrelor reaches a Cmax of 264ng/mL, with a Tmax of 3.0 hours and an AUC of 2538ng\*h/mL.
A radiolabelled dose of ticagrelor is 57.8% recovered in feces and 26.5% recovered in urine. Less than 1% of the dose is recovered as the unmetabolized parent drug. The active metabolite AC-C124910XX makes up 21.7% of the recovery in the feces. The metabolite AR-C133913XX makes up 9.2% of the recovery in the urine and 2.7% of the recovery in the feces. Other minor metabolites are predominantly recovered in the urine.
The steady state volume of distribution of ticagrelor is 88 L.
The renal clearance of ticagrelor is 0.00584L/h.
The drug is metabolized principally by cytochrome P-450 (CYP) isoenzyme 3A4 to an active metabolite that has similar antiplatelet activity as the parent drug.Plasma concentrations of ticagrelor and its active metabolite increase in a dose-dependent manner with peak concentrations achieved within approximately 1.5 and 2.5 hours, respectively. Ticagrelor is primarily eliminated in the feces and to a lesser extent in urine; less than 1% of a dose is recovered in urine as the parent drug and active metabolite. ... Both ticagrelor and its active metabolite are extensively (more than 99%) bound to human plasma proteins. Administration with a high-fat meal increases systemic exposure of ticagrelor by 21% and decreases peak plasma concentrations of the active metabolite by 22%, but has no effect on peak plasma concentrations of ticagrelor or on systemic exposure to the active metabolite.
Ticagrelor is rapidly absorbed following oral administration.
The primary route of ticagrelor elimination is hepatic metabolism. When radiolabeled ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (58% in feces, 26% in urine). Recoveries of ticagrelor and the active metabolite in urine were both less than 1% of the dose. The primary route of elimination for the major metabolite of ticagrelor is most likely to be biliary secretion.
/MILK/ It is not known whether ticagrelor or its active metabolites are excreted in human milk. Ticagrelor is excreted in rat milk.
For more Absorption, Distribution and Excretion (Complete) data for Ticagrelor (6 total), please visit the HSDB record page.
Metabolism / Metabolites
The complete structure of all ticagrelor metabolites are not well defined. Ticagrelor can be dealkylated at postition 5 of the cyclopentane ring to form the active AR-C124910XX. AR-C124910XX's cyclopentane ring can be further glucuronidated or the alkyl chain attached to the sulfur can be hydroxylated. Ticagrelor can also be glucuronidated or hydroxylated. Ticagrelor can also be N-dealkylated to form AR-C133913XX, which is further glucuronidated or hydroxylated.
CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of its major active metabolite. Ticagrelor and its major active metabolite are weak P-glycoprotein substrates and inhibitors. The systemic exposure to the active metabolite is approximately 30-40% of the exposure of ticagrelor.
The drug is metabolized principally by cytochrome P-450 (CYP) isoenzyme 3A4 to an active metabolite that has similar antiplatelet activity as the parent drug.
Ticagrelor is a reversibly binding oral P2Y(12) receptor antagonist in development for the prevention of thrombotic events in patients with acute coronary syndromes. The pharmacokinetics, metabolism, and excretion of ticagrelor were investigated over 168 hr in six healthy male subjects receiving a single oral suspension dose of 200 mg of (14)C-ticagrelor. ... Major circulating components in the plasma and feces were identified as ticagrelor and AR-C124910XX, whereas in urine the major components were metabolite M5 (AR-C133913XX) and its glucuronide conjugate M4. Levels of unchanged ticagrelor and AR-C124910XX were <0.05% in the urine, indicating that renal clearance of ticagrelor and AR-C124910XX is of minor importance. Interindividual variability was small in both urine and fecal extracts with only small quantitative differences. All 10 of the metabolites were fully or partially characterized and a full biotransformation pathway was proposed for ticagrelor, in which oxidative loss of the hydroxyethyl side chain from ticagrelor forms AR-C124910XX and a second oxidative pathway leads to N-dealkylation of ticagrelor, forming AR-C133913XX.
Biological Half-Life
Ticagrelor has a plasma half life of approximately 8 hours, while the active metabolite has a plasma half life of approximately 12 hours.
The mean terminal half-lives of ticagrelor and its active metabolite reportedly are about 7 and 9 hours, respectively.
Ticagrelor is a reversibly binding oral P2Y(12) receptor antagonist in development for the prevention of thrombotic events in patients with acute coronary syndromes. The pharmacokinetics, metabolism, and excretion of ticagrelor were investigated over 168 hr in six healthy male subjects receiving a single oral suspension dose of 200 mg of (14)C-ticagrelor. In most subjects, radioactivity was undetectable in plasma after 20 hr and whole blood after 12 hr (half-life values of 6.3 and 4.6 hr, respectively).
Toxicity/Toxicokinetics
Toxicity Summary
IDENTIFICATION AND USE: Ticagrelor is a crystalline powder. As the drug Brilinta, it is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). Brilinta also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. HUMAN EXPOSURE AND TOXICITY: Symptoms of overdose may include bleeding, gastrointestinal effects (nausea, vomiting and diarrhea) and ventricular pauses. Blood loss is the predominant risk. ANIMAL STUDIES: The acute toxicity of the drug is considered low. The results of single dose studies in mice and rats showed that ticagrelor was well tolerated when given orally by gavage at doses approximately 550 times the recommended human daily dose on a mg/kg basis. Repeat-dose studies were conducted in mice, rats and marmosets. Indications of subclinical bleeding were observed across species. Increased liver weight at high doses occurred in rodents. Ticagrelor had no effects on parturition or postnatal development in rats at doses up to 60 mg/kg/day (4.6 times the human therapeutic exposure), but did cause maternal and developmental toxicity in pups at 180 mg/kg. Ticagrelor given during the period of organogenesis had no effect on fetal development at oral doses up to 100 mg/kg/day in rats (5.1 times the human therapeutic exposure) and up to 42 mg/kg/day in rabbits (equivalent to the human therapeutic exposure). Ticagrelor and the active metabolite AR-C124910XX did not demonstrate any genotoxic potential in bacterial in vitro test, in vitro mouse lymphoma L5178Y TK+/- 3.7.2C cell, and in vivo rat bone marrow micronucleus assays.
Hepatotoxicity
In several large clinical trials, ticagrelor was not associated with serum enzyme elevations during therapy and no instances of clinically apparent liver injury were reported. While there have been isolated reports of transient and mild serum enzyme elevations during ticagrelor therapy, these have been short lived and asymptomatic. In addition, since marketing and release, there have been no reports of isolated clinically apparent liver injury or jaundice associated with ticagrelor therapy and hepatotoxicity is not mentioned in the product label. On the other hand, there have been several reports of jaundice and liver injury associated with rhabdomyolysis and with thrombotic thrombocytopenic purpura that represented secondary effects of these severe adverse events. Thus, significant liver injury due to ticagrelor occurs but has occurred largely in association with other life-threatening complications.
Likelihood score: D (possible rare cause of liver injury due to complications of severe allergic reactions or drug-drug interactions).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
No published information is available on the use of ticagrelor during breastfeeding. Because ticagrelor and its active metabolite are more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. If it is used by a nursing mother, monitor the infant for bruising and bleeding.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
Ticagrelor and its active metabolite ate >99% protein bound in plasma, particularly albumin.
Interactions
Concomitant administration of ticagrelor and digoxin did not substantially affect pharmacokinetics of digoxin; therefore, these drugs may be used concomitantly without dosage adjustments. However, because of the possibility of increased digoxin concentrations as a result of P-glycoprotein inhibition, serum digoxin concentrations should be monitored during initiation of and following any change in ticagrelor therapy.
When ticagrelor is used in conjunction with aspirin maintenance dosages exceeding 100 mg daily, efficacy of ticagrelor may be reduced.
Ticagrelor is a substrate and weak inhibitor of the P-glycoprotein transport system. Increased serum concentrations of P-glycoprotein substrates (e.g., digoxin) are possible when these drugs are used concomitantly with ticagrelor; appropriate laboratory and/or clinical monitoring is recommended.
Concomitant administration of ticagrelor and rifampin 600 mg once daily substantially decreased peak plasma concentrations of and systemic exposure to ticagrelor. Concomitant use of ticagrelor and rifampin should therefore be avoided.
For more Interactions (Complete) data for Ticagrelor (9 total), please visit the HSDB record page.
References

[1]. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128(23):2717-2728.

[2]. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136(1):234-40.

[3]. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169(1):82-9.

Additional Infomation
Therapeutic Uses
Purinergic P2Y Receptor Antagonists
/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Ticagrelor is included in the database.
Brilinta is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. /Included in US product label/
Brilinta also reduces the rate of stent thrombosis in patients who have been stented for treatment of acute coronary syndrome (ACS). /Included in US product label/
Drug Warnings
/BOXED WARNING/ BLEEDING RISK. Brilinta, like other antiplatelet agents, can cause significant, sometimes fatal bleeding. Do not use Brilinta in patients with active pathological bleeding or a history of intracranial hemorrhage. Do not start Brilinta in patients undergoing urgent coronary artery bypass graft surgery (CABG). If possible, manage bleeding without discontinuing Brilinta. Stopping Brilinta increases the risk of subsequent cardiovascular events
/BOXED WARNING/ ASPIRIN DOSE AND BRILINTA EFFECTIVENESS. Maintenance doses of aspirin above 100 mg reduce the effectiveness of Brilinta and should be avoided.
In general, treatment with ticagrelor should not be discontinued prematurely because this increases the risk of cardiovascular events. Premature discontinuance of antiplatelet therapy (e.g., P2Y12 adenosine diphosphate (ADP)-receptor antagonists, aspirin) in patients with coronary artery stents has been associated with an increased risk of ischemic cardiovascular events (e.g., stent thrombosis, myocardial infarction (MI), death). If temporary discontinuance of ticagrelor is necessary such as prior to elective surgery or for management of bleeding, the drug should be restarted as soon as possible. Patients should be advised to never stop taking ticagrelor without first consulting the prescribing clinician, even if instructed by another clinician (e.g., dentist) to stop such therapy. Prior to scheduling an invasive procedure, patients should inform clinicians (including dentists) that they are currently taking ticagrelor and clinicians performing the invasive procedure should consult with the prescribing clinician before discontinuing such therapy.
Bradyarrhythmias, including ventricular pauses, have occurred in patients receiving ticagrelor. In the The Study of Platelet Inhibition and Patient Outcomes (PLATO) study, Holter monitor-detected ventricular pauses of at least 3 seconds were reported more frequently during the first week of therapy in patients receiving ticagrelor than in those receiving clopidogrel (5.8 versus 3.6%, respectively). There was no difference in the overall risk of clinically important bradycardic effects (e.g., syncope, need for pacemaker insertion) between the treatment groups. Ventricular pauses were mostly asymptomatic and attributed to sinoatrial nodal suppression. Patients with a baseline increased risk of bradycardia (e.g., those with sick sinus syndrome, second- or third-degree AV block, syncope due to bradycardia without a pacemaker) were excluded from the PLATO study; therefore, some clinicians recommend that ticagrelor be used with caution in such patients.
For more Drug Warnings (Complete) data for Ticagrelor (15 total), please visit the HSDB record page.
Pharmacodynamics
Ticagrelor is a P2Y12 receptor antagonist that inhibits the formation of thromboses to reduce the risk of myocardial infarction and ischemic stroke. It has a moderate duration of action as it is given twice daily, and a wide therapeutic index as high single doses are well tolerated. Patients should be counselled regarding the risk of bleeding, dyspnea, and bradyarrhythmias.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C23H28F2N6O4S
Molecular Weight
522.57
Exact Mass
522.186
CAS #
274693-27-5
Related CAS #
274693-27-5
PubChem CID
9871419
Appearance
Off-white to yellow solid powder
Density
1.7±0.1 g/cm3
Boiling Point
777.6±70.0 °C at 760 mmHg
Flash Point
424.0±35.7 °C
Vapour Pressure
0.0±2.8 mmHg at 25°C
Index of Refraction
1.744
LogP
1.9
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
12
Rotatable Bond Count
10
Heavy Atom Count
36
Complexity
736
Defined Atom Stereocenter Count
6
SMILES
CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
InChi Key
OEKWJQXRCDYSHL-FNOIDJSQSA-N
InChi Code
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
Chemical Name
(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)- 3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Synonyms
AZD 6140; AZD 6140; AR-C 126532XX; AR-C-126532XX; AZD-6140; AZD6140; AR-C126532XX; Ticagrelor; brand name: Brilinta; Brilique; Possia
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage.  (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 105 mg/mL (200.9 mM)
Water:<1 mg/mL
Ethanol: 53 mg/mL (101.4 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 2 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.9136 mL 9.5681 mL 19.1362 mL
5 mM 0.3827 mL 1.9136 mL 3.8272 mL
10 mM 0.1914 mL 0.9568 mL 1.9136 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
CTID: NCT05047172
Phase: Phase 3    Status: Recruiting
Date: 2024-11-26
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
CTID: NCT06691191
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-11-15
A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
CTID: NCT06671470
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-11-04
One-Month DAPT in CABG Patients
CTID: NCT05997693
Phase: Phase 3    Status: Recruiting
Date: 2024-11-01
TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk
CTID: NCT06667349
Phase: Phase 4    Status: Completed
Date: 2024-10-31
View More

Dual Antiplatelet Therapy for Shock Patients with Acute Myocardial Infarction
CTID: NCT03551964
Phase: Phase 4    Status: Active, not recruiting
Date: 2024-10-17


A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
CTID: NCT06554821
Phase: Phase 1    Status: Completed
Date: 2024-10-15
Chewed Versus Integral Pill of Ticagrelor
CTID: NCT03708588
Phase: Phase 4    Status: Completed
Date: 2024-10-03
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
CTID: NCT06584812
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-09-25
Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage
CTID: NCT05986968
Phase: N/A    Status: Recruiting
Date: 2024-09-23
Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA
CTID: NCT06591338
Phase: Phase 3    Status: Recruiting
Date: 2024-09-19
Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA
CTID: NCT06591312
Phase: Phase 3    Status: Recruiting
Date: 2024-09-19
Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA
CTID: NCT06591390
Phase: Phase 3    Status: Recruiting
Date: 2024-09-19
Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA
CTID: NCT06591377
Phase: Phase 3    Status: Recruiting
Date: 2024-09-19
Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke
CTID: NCT06202755
Phase: Phase 3    Status: Recruiting
Date: 2024-08-20
Ticagrelor Versus Cilostazol in Ischemic Stroke
CTID: NCT06561867
Phase: Phase 3    Status: Recruiting
Date: 2024-08-20
Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA
CTID: NCT06196047
Phase: Phase 3    Status: Recruiting
Date: 2024-08-20
Ticagrelore Alone Post PCI
CTID: NCT06509893
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-07-30
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
CTID: NCT04483583
Phase: Phase 4    Status: Active, not recruiting
Date: 2024-07-18
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
CTID: NCT02016170
Phase: N/A    Status: Completed
Date: 2024-07-03
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
CTID: NCT06451198
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-06-18
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
CTID: NCT04240834
Phase: Phase 4    Status: Recruiting
Date: 2024-06-18
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
CTID: NCT05476991
Phase: Phase 3    Status: Recruiting
Date: 2024-06-03
Ticagrelor Monotherapy After Stenting
CTID: NCT05149560
Phase: Phase 2    Status: Recruiting
Date: 2024-05-16
Ticagrelor Versus Clopidogrel in Ischemic Stroke
CTID: NCT05553613
Phase: Phase 3    Status: Completed
Date: 2024-05-14
CES1 Crossover Trial of Clopidogrel and Ticagrelor
CTID: NCT03161678
Phase: Phase 4    Status: Completed
Date: 2024-05-06
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
CTID: NCT06228456
Phase: Phase 4    Status: Recruiting
Date: 2024-04-23
P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold
CTID: NCT03119012
Phase: Phase 4    Status: Terminated
Date: 2024-04-22
A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients
CTID: NCT04307511
Phase: Phase 4    Status: Recruiting
Date: 2024-04-22
TADCLOT- a Double Blind Randomized Controlled Trial
CTID: NCT06318481
Phase: Phase 3    Status: Recruiting
Date: 2024-03-19
A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge
CTID: NCT06301776
Phase: N/A    Status: Recruiting
Date: 2024-03-08
Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions
CTID: NCT05209412
Phase: N/A    Status: Active, not recruiting
Date: 2024-01-24
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
CTID: NCT03476369
Phase: Phase 4    Status: Recruiting
Date: 2024-01-24
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
CTID: NCT04007055
Phase: Phase 3    Status: Recruiting
Date: 2024-01-05
Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke
CTID: NCT06120725
Phase: Phase 3    Status: Completed
Date: 2023-12-29
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
CTID: NCT05566301
Phase:    Status: Recruiting
Date: 2023-12-28
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
CTID: NCT04588727
Phase: Phase 1    Status: Completed
Date: 2023-12-18
A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients
CTID: NCT04255602
Phase: Phase 4    Status: Recruiting
Date: 2023-12-07
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
CTID: NCT05093790
Phase: Phase 2    Status: Completed
Date: 2023-12-05
1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon
CTID: NCT04971356
Phase: N/A    Status: Active, not recruiting
Date: 2023-11-14
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes
CTID: NCT04057300
Phase: Phase 4    Status: Completed
Date: 2023-11-03
Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke
CTID: NCT04738097
Phase: Phase 3    Status: Completed
Date: 2023-10-19
Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease
CTID: NCT06088433
Phase: Phase 4    Status: Not yet recruiting
Date: 2023-10-18
A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients
CTID: NCT04307485
Phase: Phase 4    Status: Recruiting
Date: 2023-10-06
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
CTID: NCT05116995
Phase: Phase 4    Status: Recruiting
Date: 2023-09-22
Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data
CTID: NCT05086081
Phase:    Status: Completed
Date: 2023-07-27
Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data
CTID: NCT04237935
Phase:    Status: Completed
Date: 2023-07-27
Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI
CTID: NCT05911659
Phase:    Status: Recruiting
Date: 2023-06-22
Ticagrelor vs. Clopidogrel in Post PCI Patients
CTID: NCT05858918
Phase: N/A    Status: Completed
Date: 2023-05-16
De-escalation of Ticagrelor in Post PPCI
CTID: NCT05831462
Phase: Phase 1/Phase 2    Status: Not yet recruiting
Date: 2023-04-26
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
CTID: NCT04006288
Phase: Phase 4    Status: Completed
Date: 2023-04-26
Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome
CTID: NCT04718025
Phase: Phase 3    Status: Recruiting
Date: 2023-04-21
Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study
CTID: NCT03251859
Phase: Phase 3    Status: Completed
Date: 2023-04-21
Safety of 'Ticagrelor+ Warfarin'in Comparison With 'Clopidogrel+Aspirin+Warfarin'
CTID: NCT02206815
Phase: Phase 4    Status: Completed
Date: 2023-04-14
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
CTID: NCT03869268
Phase: Phase 4    Status: Completed
Date: 2023-04-13
Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy
CTID: NCT04766437
Phase: Phase 2    Status: Completed
Date: 2023-03-06
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
CTID: NCT01944800
Phase: Phase 4    Status: Completed
Date: 2023-02-06
The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention
CTID: NCT03331484
Phase: Phase 3    Status: Active, not recruiting
Date: 2023-01-17
ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome
CTID: NCT03129867
Phase:    Status: Completed
Date: 2023-01-12
Chronic Kidney Disease (CKD) Platelet Study
CTID: NCT03649711
Phase: Phase 3    Status: Completed
Date: 2022-12-29
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study
CTID: NCT05643586
Phase: Phase 4    Status: Completed
Date: 2022-12-08
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
CTID: NCT03430661
Phase: Phase 1    Status: Completed
Date: 2022-11-16
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
CTID: NCT02053909
Phase: Phase 4    Status: Completed
Date: 2022-09-14
Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition
CTID: NCT04941196
Phase: Phase 1    Status: Completed
Date: 2022-09-08
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile
CTID: NCT05516784
Phase: Phase 4    Status: Completed
Date: 2022-09-01
A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA
CTID: NCT05476081
Phase:    Status: Unknown status
Date: 2022-08-02
Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence
CTID: NCT05474053
Phase: Phase 3    Status: Completed
Date: 2022-07-26
SAPT Versus DAPT in Incomplete Revascularization After CABG
CTID: NCT03789916
Phase: Phase 3    Status: Recruiting
Date: 2022-07-21
Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)
CTID: NCT02486367
Phase: Phase 4    Status: Completed
Date: 2022-07-20
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
CTID: NCT04739384
Phase: Phase 3    Status: Completed
Date: 2022-07-07
Ticagrelor Versus Clopidogrel in Carotid Artery Stenting
CTID: NCT02677545
Phase: Phase 2    Status: Completed
Date: 2022-06-28
The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome
CTID: NCT02484924
Phase:    Status: Completed
Date: 2022-06-09
Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
CTID: NCT02335099
Phase: Phase 1/Phase 2    Status: Completed
Date: 2022-06-08
KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug
CTID: NCT05373277
Phase: Phase 1    Status: Unknown status
Date: 2022-05-13
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
CTID: NCT05283356
Phase: Phase 4    Status: Recruiting
Date: 2022-03-31
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
CTID: NCT02325466
Phase: Phase 3    Status: Completed
Date: 2022-03-21
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
CTID: NCT05183178
Phase: Phase 4    Status: Recruiting
Date: 2022-03-17
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
CTID: NCT01813435
Phase: Phase 3    Status: Completed
Date: 2022-03-15
GM03 - Platelet RNA Signatures of Aspirin
CTID: NCT05278637
PhaseEarly Phase 1    Status: Completed
Date: 2022-03-14
Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation
CTID: NCT04331145
Phase: Phase 4    Status: Completed
Date: 2022-03-02
Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel
CTID: NCT05247385
Phase: Phase 4    Status: Completed
Date: 2022-02-18
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
CTID: NCT02539160
Phase: Phase 4    Status: Completed
Date: 2022-01-28
Optimal Dosage of Ticagrelor in Korean Patients With AMI
CTID: NCT05210595
Phase: Phase 4    Status: Unknown status
Date: 2022-01-27
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
CTID: NCT04001894
Phase: Phase 4    Status: Completed
Date: 2022-01-11
Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass
CTID: NCT05166538
Phase: Phase 4    Status: Unknown status
Date: 2021-12-22
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
CTID: NCT03679091
Phase: Phase 4    Status: Completed
Date: 2021-12-21
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
CTID: NCT03437044
Phase: Phase 4    Status: Completed
Date: 2021-11-30
Tailored Antiplatelet Therapy Following PCI
CTID: NCT01742117
Phase: Phase 4    Status: Completed
Date: 2021-11-09
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
CTID: NCT04695106
Phase: Phase 4    Status: Recruiting
Date: 2021-11-04
Impact of Anti-platelet Drug Exposure on Platelet mRNA Splicing in Healthy Subjects
CTID: NCT04088123
Phase:    Status: Withdrawn
Date: 2021-10-28
Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
CTID: NCT02874092
Phase: Phase 4    Status: Completed
Date: 2021-10-25
The Antiplatelet and Immune Response Trial
CTID: NCT01846559
Phase: Phase 4    Status: Completed
Date: 2021-09-27
Ticagrelor Administered as Standard Tablet or Orodispersible Formulation
CTID: NCT03822377
Phase: Phase 3    Status: Completed
Date: 2021-09-08
Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients
CTID: NCT02639143
Phase: Phase 4    Status: Completed
Date: 2021-08-23
Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI
CTID: NCT03078465
Phase: Phase 3    Status: Withdrawn
Date: 2021-08-19
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
CTID: NCT04999293
Phase:    Status: Completed
Date: 2021-08-10
Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm
CTID: NCT02675205
Phase: Phase 3    Status: Completed
Date: 2021-07-16
Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke
CTID: NCT04962451
Phase: Phase 4    Status: Completed
Date: 2021-07-15
Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia
CTID: NCT02230527
Phase: Phase 2/Phase 3    Status: Terminated
Date: 2021-07-07
Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)
CTID: NCT04946929
Phase: Phase 3    Status: Unknown status
Date: 2021-07-01
Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome
CTID: NCT02341729
Phase: Phase 4    Status: Completed
Date: 2021-05-10
PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
CTID: NCT03492931
Phase: Phase 1    Status: Completed
Date: 2021-05-10
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
CTID: NCT04688723
Phase: Phase 4    Status: Unknown status
Date: 2021-04-30
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
CTID: NCT03615924
Phase: Phase 3    Status: Terminated
Date: 2021-04-09
NIRS Ticagrelor Evaluation
CTID: NCT02282332
Phase: Phase 4    Status: Completed
Date: 2021-04-08
TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI
CTID: NCT02018055
Phase: Phase 4    Status: Completed
Date: 2021-04-02
Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting
CTID: NCT04091074
Phase: Phase 1    Status: Unknown status
Date: 2021-03-23
Ticagrelor De-escalation Strategy in East Asian Patients With AMI
CTID: NCT04755387
Phase: Phase 4    Status: Unknown status
Date: 2021-02-16
Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)
CTID: NCT04734353
Phase: Phase 4    Status: Unknown status
Date: 2021-02-02
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
CTID: NCT03357874
Phase: Phase 3    Status: Unknown status
Date: 2021-01-22
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
CTID: NCT02270242
Phase: Phase 4    Status: Completed
Date: 2021-01-13
Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
CTID: NCT02931045
Phase: Phase 4    Status: Completed
Date: 2020-12-23
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
CTID: NCT03354429
Phase: Phase 3    Status: Completed
Date: 2020-12-22
Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome
CTID: NCT04630288
Phase:    Status: Unknown status
Date: 2020-11-16
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting
CTID: NCT02617290
Phase: Phase 3    Status: Completed
Date: 2020-10-14
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
CTID: NCT03489863
Phase: Phase 4    Status: Completed
Date: 2020-09-16
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease
CTID: NCT02287909
Phase: Phase 4    Status: Completed
Date: 2020-09-16
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
CTID: NCT02545933
Phase: Phase 4    Status: Completed
Date: 2020-09-16
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
CTID: NCT02065479
Phase: Phase 4    Status: Completed
Date: 2020-09-16
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
CTID: NCT02944123
Phase: Phase 3    Status: Completed
Date: 2020-08-20
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
CTID: NCT01955200
Phase: Phase 4    Status: Completed
Date: 2020-08-18
ADHERE-S (NIS Brilique)
CTID: NCT03444012
Phase:    Status: Completed
Date: 2020-08-07
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
CTID: NCT04293172
Phase: Phase 3    Status: Withdrawn
Date: 2020-07-15
Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
CTID: NCT02531165
Phase: N/A    Status: Completed
Date: 2020-07-15
A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response
CTID: NCT03027934
Phase: Phase 4    Status: Withdrawn
Date: 2020-07-15
Comparison of CABG Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel
CTID: NCT04431349
Phase:    Status: Completed
Date: 2020-06-16
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
CTID: NCT04206176
Phase: Phase 1/Phase 2    Status: Completed
Date: 2020-05-21
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
CTID: NCT02866175
Phase: Phase 3    Status: Completed
Date: 2020-05-06
Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel
CTID: NCT02925923
Phase: Phase 2    Status: Completed
Date: 2020-05-04
Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction
CTID: NCT04369534
Phase: Phase 4    Status: Completed
Date: 2020-04-30
The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery
COATS study: genetic Clopidogrel response testing to finetune the antithrombotic regimen in (D)OAC Treated patients undergoing PCI
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2022-10-03
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2022-07-26
Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention
CTID: null
Phase: Phase 4    Status: Trial now transitioned
Date: 2022-04-21
Single antiplatelet therapy with Ticagrelor vs Aspirin after Transcatheter Aortic Valve Implantation: multicenter randomized clinical trial. REAC TAVI 2
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2021-10-15
Evaluation of safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in acute coronary syndrome: the randomized, multicentre, double-blind ELECTRA RCT study.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2021-09-30
Novel therapeutic strategies to reduce coronary microvascular obstruction and to OPTImize non-culprit stenoses revascularization in ST-Elevation acute Myocardial Infarction
CTID: null
Phase: Phase 2    Status: Completed
Date: 2021-07-09
Tailoring P2Y12 Inhibiting Therapy in Patients requiring Oral Anticoagulation after undergoing Percutaneous Coronary Intervention: The Switching Anti-Platelet and Anti-Coagulant Therapy – 2 Study
CTID: null
Phase: Phase 4    Status: Completed
Date: 2021-06-24
AlteRnative antIthrombotic pathwayS in acutE myocardial infarction:
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2021-04-21
Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2021-04-14
Optical Coherence Tomography-Guided PCI with Single-Antiplatelet Therapy
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2021-01-29
Platelet inhibition with Ticagrelor 60 mg versus Ticagrelor 90 mg twice daily in elderly patients with acute coronary syndrome (ACS).
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2021-01-08
REACTIC-TAVI TRIAL: Platelet REACtivity according to TICagrelor dose after Trancathter Aortic Valve Implantation. A pilot study.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2020-05-22
Assessment of Loading with the P2Y12 inhibitor Ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting: the ALPHEUS study.
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2019-11-19
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2019-08-05
Cost-effectiveness of CYP2C19 guided treatment with antiplatelet drugs in patients with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention with stent implantation
CTID: null
Phase: Phase 4    Status: Completed
Date: 2019-04-23
The impact of aspirin dose modification on the innate immune response - WILL lOWer dose aspirin Therapy ReducE the response to Endotoxin? – (WILLOW TREE)
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2019-01-18
Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy (DAPT) improve thrombotic status in acute coronary syndrome (ACS)
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2018-10-22
Single versus Dual Antiplatelet Therapy in patients with Incomplete Revascularization after Coronary artery bypass graft surgery
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2018-10-16
A randomized trial of the effect of antiplatelet therapy (Aspirin, Aspirin and Clopidogrel or Ticagrelor) on the occurrence of atherothrombotic and cardiovascular adverse events following lower extremity perctaneous transluminal angioplasty.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2018-09-03
A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Ra e.querySelector("font strong").innerText = 'View More' } else if(up_display === 'none' || up_display === '') { icon_angle_down.style.display = '

Biological Data
Contact Us